Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sandra Wear"'
Autor:
Sandra Wear, Irene M. Ghobrial, Daniel C. Sullivan, Nora Loughney, Lisa A. Nardelli, David S. Siegel, Robert L. Schlossman, Min Chen, Melissa Alsina, Paul G. Richardson, Susan L. Kelley, Palka Anand, Elizabeth Bilotti, Gail Larkins, Kenneth C. Anderson, M. Zaki, Jacob P. Laubach, Nikhil C. Munshi, Christian Jacques, Deborah Doss, Laura McBride, Rachid Baz
Publikováno v:
Blood. 121:1961-1967
This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34238257ec5674606789e9389d44123b
https://doi.org/10.1182/blood-2012-08-450742
https://doi.org/10.1182/blood-2012-08-450742
Autor:
Suzanne Trudel, Sundar Jagannath, George Somlo, Andrzej Jakubowiak, Sagar Lonial, Jeffrey A. Zonder, Ravi Vij, Francis K. Buadi, Nizar J. Bahlis, Frederic J. Reu, Sandra Wear, Michael Wang, Lori Kunkel, Robert Z. Orlowski, David S. Siegel, Asher Chanan-Khan, Vishal Kukreti, Alvin F. Wong, Melissa Alsina, Edward A. Stadtmauer, Thomas Martin, A. Keith Stewart, Kevin W. Song
Publikováno v:
Blood. 120(14)
Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb5be6e61cf93f6a9685a53967f4173
https://pubmed.ncbi.nlm.nih.gov/23043023
https://pubmed.ncbi.nlm.nih.gov/23043023
Autor:
David S. Siegel, Sagar Lonial, Robert Z. Orlowski, Michael Wang, Michael Sebag, Alvin F. Wong, Lori Kunkel, Jonathan L. Kaufman, Nizar J. Bahlis, Andrzej Jakubowiak, Sandra Wear, Ravi Vij, Nashat Gabrail, Frederic J. Reu, Peter P. Lee, Melissa Alsina, Jeffrey Matous, Andrew R. Belch, Sundar Jagannath, David H. Vesole, A. Keith Stewart, Peter Rosen, Vishal Kukreti, Kevin T. McDonagh
Publikováno v:
Blood. 119(24)
Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f30e9cd2f0017214e9aedd4faa465756
https://pubmed.ncbi.nlm.nih.gov/22555973
https://pubmed.ncbi.nlm.nih.gov/22555973
Autor:
Kevin T. McDonagh, Andrzej Jakubowiak, Sandra Wear, Michael Wang, Nizar J. Bahlis, Robert Z. Orlowski, Alexander Keith Stewart, David S. Siegel, Andrew Belch, Alvin F. Wong, Lori Kunkel, Sundar Jagannath, Ravi Vij
Publikováno v:
British journal of haematology. 158(6)
Summary Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99cae847d6d682ea23a1f6c8d33747ff
https://pubmed.ncbi.nlm.nih.gov/22845873
https://pubmed.ncbi.nlm.nih.gov/22845873
Autor:
Jennifer Barrickman, Tara B. Anderson, Colleen K. Harvey, Erica L. Campagnaro, Andrzej Jakubowiak, Donna E. Reece, Mark S. Kaminski, Craig L. Tendler, Melissa A. Mietzel, Dixie Lee Esseltine, Robert L. Schlossman, Noopur Raje, S. Lonial, Todd M. Zimmerman, Sandra Wear, Kenneth C. Anderson, Kent A. Griffith, Jacob P. Laubach, Craig C. Hofmeister, Paul G. Richardson, Susan L. Kelley
Publikováno v:
Blood. 118(3)
This phase 1/2 trial evaluated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly diagnosed multiple myeloma (MM) patients. Patients received RVDD at 4 dose levels, including the maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d50aac9032358498eaf99ad2f61bac
https://pubmed.ncbi.nlm.nih.gov/21596852
https://pubmed.ncbi.nlm.nih.gov/21596852
Autor:
Keith Stockerl-Goldstein, Sundar Jagannath, Tara B. Anderson, Ammar Al-Zoubi, Ravi Vij, Daniel Lebovic, Asra Ahmed, Dominik Dytfeld, Andrzej Jakubowiak, Daniel R. Couriel, Mark S. Kaminski, Sandra Wear, Kristen Detweiler-Short, Homa Yeganegi, Mohamad A. Hussein, Kent A. Griffith, Terri L. Jobkar, David H. Vesole, Melissa A. Mietzel, Brian K. Nordgren
Publikováno v:
Journal of Clinical Oncology. 30:8011-8011
8011 Background: Combination treatment (tx) with CFZ, LEN, and DEX (CRd) is well tolerated and highly active in NDMM. In a phase 1/2 study, CRd provided rapid reduction of disease by 68% after cycle (C) 1 and 94% ≥partial response (PR) at a median
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fd2b02fb36a1e28894dcc3a55ed53eb
https://doi.org/10.1200/jco.2012.30.15_suppl.8011
https://doi.org/10.1200/jco.2012.30.15_suppl.8011
Autor:
Jennifer Houp, Hartmut Goldschmidt, Jason Howe, L. Sun, Meletios A. Dimopoulos, David S. Siegel, Donna E. Reece, Simon Durrant, Sung-Soo Yoon, Xavier Leleu, Thorsten Graef, Arnon Nagler, Sandra Wear, Fritz Offner, Kenneth C. Anderson, Michele Cavo, Sundar Jagannath, Jonathan L. Kaufman, Jacob P. Laubach
Publikováno v:
Blood. 118:480-480
Abstract 480 Introduction: Vorinostat (VOR), an oral inhibitor of histone deacetylase (HDAC) class I and class II proteins, affects pathways regulating cell proliferation and apoptosis in a diverse array of tumor types. Phase 1/2 trials in multiple m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bf0281f678c927588adf8b456437f28
https://doi.org/10.1182/blood.v118.21.480.480
https://doi.org/10.1182/blood.v118.21.480.480
Autor:
Todd M. Zimmerman, Sandra Wear, Ravi Vij, Rachel Hagerty, Mark A. Fiala, Engin Gul, Amrita Krishnan, Robert F Ott, Noopur Raje, Donna E. Reece, Mindy A Bowers, Michele Maharaj, Ann Birgin, Vivek Roy, Leah Tasca, Sundar Jagannath, David S. Siegel, Shaji Kumar, Alaina R. Mitchell, Paul G. Richardson, Adolfo Aleman, Daniel Larsen, Kathy Giusti, Sagar Lonial, Jeffrey L. Wolf, Lupe Duarte, Lisa La, A. Keith Stewart, Joseph W. Fay, Carolyn Revta, Diane E. Durecki, Kenneth C. Anderson, Craig C. Hofmeister, Tracey Messing, Geraldine Pelle-Day, Andrzej Jakubowiak, Ajai Chari
Publikováno v:
Blood. 118:1024-1024
Abstract 1024 Background: The MMRC is a non-profit, disease-focused consortium founded in 2004. Sixteen North American member institutions with expertise in multiple myeloma (MM) work collaboratively with the MMRC Inc. (Norwalk, CT) and numerous phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e6697bbed70f74939a30f0c48075260
https://doi.org/10.1182/blood.v118.21.1024.1024
https://doi.org/10.1182/blood.v118.21.1024.1024
Autor:
Andrzej Jakubowiak, Diane E. Durecki, Kent A. Griffith, Brian K. Nordgren, Tara B. Anderson, Robert F Ott, Ammar Al-Zoubi, Melissa A. Mietzel, Ravi Vij, Joseph A Leveque, Dominik Dytfeld, Daniel R. Couriel, Mohamad A. Hussein, David H. Vesole, Keith Stockerl-Goldstein, Terri L. Jobkar, Kristen Detweiler-Short, Sundar Jagannath, Sandra Wear, Daniel Lebovic
Publikováno v:
Blood. 118:631-631
Abstract 631 Introduction: In relapsed and/or refractory MM, the combination of carfilzomib (CFZ) with lenalidomide (Len), and low-dose dexamethasone (Dex) (CRd) has shown very promising efficacy (78% ≥partial response [PR], 40% ≥very good partia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1559de63a4e89c90683c62fedfddbc26
https://doi.org/10.1182/blood.v118.21.631.631
https://doi.org/10.1182/blood.v118.21.631.631
Autor:
Jonathan L. Kaufman, Ravi Vij, Vishal Kukreti, Kevin T. McDonagh, Nizar J. Bahlis, Melissa Alsina, Peter P. Lee, Sundar Jagannath, Keith Stewart, Lori Kunkel, Andrzej Jakubowiak, David H. Vesole, Nashat Y. Gabrail, Jeffrey Matous, Robert Z. Orlowski, Michael Wang, Frederic J. Reu, Alvin F. Wong, Andrew Belch, Sandra Wear
Publikováno v:
Blood. 118:813-813
Abstract 813FN2 Introduction: Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition absent of off-target effects relative to bortezomib. Carfilzomib has demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d23c78bc60c6c6b1f75cf1141a624342
https://doi.org/10.1182/blood.v118.21.813.813
https://doi.org/10.1182/blood.v118.21.813.813